CLL Associated studies
Open trials
| Short name | BGB-16673-304 |
| Study title | A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Pirtobrutinib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors |
| Population | Relapse / refractory CLL |
| Participants | Universitair Medisch Centrum Utrecht - De Haart Universitair Medisch Centrum Groningen – Bellido Albert Schweitzer Ziekenhuis – Levin Canisius Wilhelmina Ziekenhuis – De Jonge Catharina Ziekenhuis - Nijziel |
| Study docs | Eligibility criteria |
| Short name | BGB-16673-302 |
| Study title | A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors |
| Population | Relapse / refractory CLL |
| Participants | AmsterdamUMC - Kater |
| Study docs | Eligibility criteria |
| Short name | BGB-11417-304 |
| Study title | A Phase 3, Open-Label, Randomized Study of Sonrotoclax-Zanubrutinib vs Venetoclax-Acalabrutinib in Treatment naive Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Population | Treatment naive CLL |
| Participants | Flevoziekenhuis - Kater / de Heer Hagaziekenhuis - Kersting Albert Schweitzer Ziekenhuis – Levin |
| Study docs | Eligibility criteria |
| Short name | CELESTIAL-TNCLL study |
| Study title | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia. |
| Status | Open |
| Reference | Clinicaltrials.gov: NCT06073821 |
| Population |
Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment, 18 Years and older (Adult, Older Adult) |
| Participants |
Martini Ziekenhuis - Groningen - Schreurs |
| Study docs | Eligibility criteria |
| Short name | M18-803 T-PLL |
| Study title | A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-Cell Prolymphocytic Leukemia |
| Reference | Clinicaltrials.gov: NCT03873493 |
| Status | Open |
| Participants | M. Bellido, Universitair Medisch Centrum, Groningen; m.bellido@umcg.nl L. Tick, Maxima Medisch Centrum, Eindhoven; l.Tick@mmc.nl |
| Study docs | Eligibility criteria |
| Short name | ACE-CL-311 |
| Study title | A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation. |
| Reference | Clinicaltrials.gov: NCT04008706 |
| Status | Open |
| Participants | AmsterdamUMC - location AMC – Arnon Kater Flevoziekenhuis – Koen de Heer |
| Study docs | Flow + Eligibility criteria |
| Short name | ACE-CL-312 |
| Study title | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia |
| Reference | Clinicaltrials.gov: NCT04008706 |
| Status | Open only for patients with prior BTKi therapy (Cohort3) (Other cohorts: Treatment-naive patients and enrollment of patients with Relapsed/Refractory disease are complete) |
| Participants | Open in: Universitair Medisch Centrum Utrecht (Utrecht) Rogier Mous (r.mous@umcutrecht.nl) Will also be opened in: Albert Schweitzer Ziekenhuis (Dordrecht), Mark-David Levin HagaZiekenhuis (Den Haag), Sabina Kersting Rijnstate Ziekenhuis (Arnhem) Ellen vd Spek Isala Klinieken (Zwolle), Ellen Dompeling |
| Study docs | Flow + Eligibility criteria |